Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells

Blood

Volumn 109, Issue 10, 2007, Pages 4399-4405

  Venturini, Letizia ^a   Battmer, Karin ^a   Castoldi, Mirco ^b   Schultheis, Beate ^c   Hochhaus, Andreas ^c   Muckenthaler, Martina U ^b   Ganser, Arnold ^a   Eder, Matthias ^a   Scherr, Michaela ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; MICRORNA; MYC PROTEIN;

ARTICLE; CD34 SELECTION; CELL DEATH; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 34248398096     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-09-045104     Document Type: Article

References (29)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-297.
2. Lee Y, Ahn C, Han J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature. 2003;425:415-419.
3. Ambros V. The functions of animal microRNAs. Nature. 2004;431:350-355.
4. Thomson JM, Newman M, Parker JS, Morin-Kensicki EM, Wright T, Hammond SM. Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev. 2006;20:2202-2207.
5. Metzler M, Wilda M, Busch K, et al. High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma. Genes Chromosom Cancer. 2004;39:167-169.
6. Calin GA, Liu CG, Sevignani C, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A. 2004;101:11755-11760.
7. Calin CA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004;101:2999-3004.
8. Hayashita Y, Osada H, Tatematsu Y, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 2005;65:9628-9632.
9. Johnson SM, Grisshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell. 2005;120:635-647.
10. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834-838.
11. Tanzer A, Stadler PF. Molecular evolution of a microRNA cluster. J Mol Biol. 2004;339:327-335.
12. Scherr M, Battmer K, Blomer U, et al. Lentiviral gene transfer into peripheral blood-derived CD34+ NOD/SCID-repopulating cells. Blood. 2002;99:709-712.
13. Ota A, Tagawa H, Karnan S, et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res. 2004;64:3087-3095.
14. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature. 2005;35:828-833.
15. O'Donnell KA, Wentzel EA, Zeller KI, et al. c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 2005;35:839-843.
16. Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes. Cell. 1992;70:901-910.
17. Castoldi M, Schmidt S, Benes V, et al. A sensitive array for microRNA expression profiling (miChip) based on locked nucleic acids (LNA). RNA. 2006;12:913-920.
18. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402-408.
19. Van de Wetering M, Oving I, Muncan V, et al. Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector. EMBO Rep. 2003;4:609-615.
20. Scherr M, Battmer K, Ganser A, et al. Modulation of gene expression by lentiviral-mediated delivery of small interfering RNA. Cell Cycle. 2003;2:251-257.
21. Scherr M, Battmer K, Schultheis B, et al. Stable RNA interference (RNAi) as an option for anti-bcr-abl therapy. Gene Ther. 2005;12:12-21.
22. Skorski T, Bellacosa A, Nieborowska-Skorska M, et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a Pl-3k/Akt-dependent pathway. EMBO J. 1997;16:6151-6161.
23. Okuda K, D'Andrea A, Van Etten RA, Griffin JD. The C-terminus of c-ABL is required for proliferation and viability signaling in a c-ABL/erythropoietin receptor fusion protein. Blood. 1998;92:3848-3856.
24. Xie S, Lin H, Sun T, Arlinghaus RB. Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene. 2002;21:7137-7146.
25. Levens D. Disentangling the MYC web. Proc Natl Acad Sci U S A. 2002;99:5757-5759.
26. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. Semin Cancer Biol. 2006;16:253-264.
27. Lewis BP, Shih IH, Jones-Rhoades MW. Prediction of mammalian micro RNA targets. Cell. 2003;115:787-798.
28. Volinia S, Calin GA, Liu CG. A micro RNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103:2257-2261.
29. Krutzfeld J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature. 2005;438:685-689.